Indonesia Generics Market Summary, Competitive Analysis and Forecast to 2027

Key Highlights

• For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. The market value is evaluated at ex-factory prices.
• The Indonesian generics market had total revenues of $1.5 billion in 2022, representing a compound annual growth rate (CAGR) of 10.2% between 2017 and 2022.
• Market consumption volume increased with a CAGR of 1.1% between 2017 and 2022, to reach a total of 50.7% in 2022.
• The consumption of generic medication is expanding due to its lower cost than patented original medications, giving them an edge in volume-based procurement settings where there is intense price rivalry.

Scope

• Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Indonesia
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Indonesia
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia generics market with five year forecasts

Reasons to Buy

• What was the size of the Indonesia generics market by value in 2022?
• What will be the size of the Indonesia generics market in 2027?
• What factors are affecting the strength of competition in the Indonesia generics market?
• How has the market performed over the last five years?
• What are the main segments that make up Indonesia's generics market?